Is Alaunos Therapeutics, Inc. overvalued or undervalued?

Jun 25 2025 08:48 AM IST
share
Share Via
As of November 14, 2023, Alaunos Therapeutics, Inc. is considered overvalued with a valuation grade of "does not qualify" due to significant negative financial ratios, including a Price to Book Value of 4.70 and a ROCE of -416.30%, despite a recent stock price surge.
As of 14 November 2023, Alaunos Therapeutics, Inc. has moved from a valuation grade of risky to does not qualify. The company is currently considered overvalued, given its significant negative financial ratios, including a Price to Book Value of 4.70 and an EV to EBITDA of -1.12. The return on capital employed (ROCE) is alarmingly low at -416.30%, indicating severe operational inefficiencies.

In comparison to its peers, Alaunos Therapeutics has a worse EV to EBITDA ratio than MAIA Biotechnology, Inc. at -2.1328 and MiNK Therapeutics, Inc. at -3.4718, both of which also do not qualify for a positive valuation. Despite a recent surge in stock price with a 1-month return of 68.42%, the overall financial health and valuation metrics suggest that the company remains overvalued in the current market landscape.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
What does Alaunos Therapeutics, Inc. do?
Jun 22 2025 06:34 PM IST
share
Share Via
How big is Alaunos Therapeutics, Inc.?
Jun 22 2025 05:55 PM IST
share
Share Via